HRP Risk Approach Plans

For the Human Health Countermeasures Element

June 2026

Index of Legend Symbols

M2M Deliverable

Lunar Deliverable

For Data Field

Brookhaven National Laboratory

For Legend


Animal Models


Artemis


Atmospheric Chamber


Bedrest


Centrifuge


CLDP

Brookhaven National Laboratory

For Data Field



For Legend


Commercial Freeflyers/PAM


Drop tower/sled


Isolation


ISS


Neutral Buoyancy Lab


Parabolic Flight

Organization Graphic Identifiers

Extravehicular Activity and Human Surface Mobility


Commercial Crew

Human Landing Systems

Flight Operations

Office of the Chief Health and Medical Officer

Mars Campaign Office

Health and Medical Technical Authority

Bone Risk Approach Plan

HRR Knowledge Gap

Risk Characterization / Formulation

BONE-101: Characterize changes in **bone density and structure** (quality) in astronauts.

BONE-102: Characterize **bone turnover and other biochemical markers** of skeletal health.

BONE-201: Identify/develop/apply tools (e.g., computational modeling or alternative) to inform the **estimation bone strength and probability of overloading bones and fracture assessment**.

BONE-301: Identify, develop, and implement **monitoring tools** for bone health following long-duration spaceflight.

1 **Bone Standards and Recommendations: OCHMO by 2028**
MRI Informing Pharmaceutical Use TTO 2027

CM Development / Evaluation

BONE-401: Identify and test preventative and mitigating **countermeasures** for changes induced by spaceflight.

1 **Bone Standards and Recommendations: OCHMO by 2028**
MRI Informing Pharmaceutical Use TTO 2027

LEGEND: Isolation ISS M2M Deliverable

TIMELINE:

2025 — 1 — 2030 — 2035

Risk Maps to ESDMD–0401

EVA Risk Approach Plan

HRR Knowledge Gap

Risk Characterization / Formulation

EVA-101: Characterize **EVA preparedness** shortly post-landing on a planetary surface.

1 **Days post-landing prior to initial EVA: OCHMO by 2027**

EVA-102: Characterize **surface EVA performance** during exploration missions in partial gravity environments.

2a **Lunar Hi-Tempo Capabilities: EHP/FOD/OCHMO by 2028**

2b **Martian Hi-Tempo Capabilities: EHP/FOD/OCHMO by 2029**

EVA-201: Characterize impacts of **variable atmospheric conditions suits** on human health and performance, including exploration atmospheres, variable pressure suits, and alternate pre-breathe strategies.

3 **Elevated Suit Pressure Trade Space (EHP/HRP): EHP/FOD by 2028**

4 **DCS Risk Prediction Tool: EHP/OCHMO by 2030**

Initial model updates and implementation by 2027

CM Development / Evaluation

EVA-303: Identify and test **countermeasures related to exposure to variable atmospheric conditions**.

5 **Integrated DCS CM (e.g. CO_2, exercise, PFO, suit pressure): EHP/HLS by 2030**

CO_2–enhanced prebreathe evaluated by 2027

Exercise-enhanced prebreathe evaluated by 2027

PFO initial analysis by 2027

LEGEND: ISS · CLDP · Commercial Freeflyers/PAM · Neutral Buoyancy Lab · Atmospheric Chamber · Artemis · M2M Deliverable · Lunar Deliverable

TIMELINE:

DCS

1 — 2 — 3 — 4 — 5

2025 — 2029 — 2031 — 2035

Risk Maps to ESDMD–0406 and 0803

Food and Nutrition Risk Approach Plan

HRR Knowledge Gap

Risk Characterization / Formulation

FN-103: **Influence of temperature** on the nutritional content, safety, and acceptability of the spaceflight food system.

1. **Cold Storage Temperature Requirements - Mars: M2M by 2027**
2. **HLS Palatability and Nutrition of Food Stored at High Temps: M2M by 2028**

CM Development / Evaluation

FN-206: Using **food as a countermeasure** to mitigate decrements in nutritional status or DRM impacts on health and performance outcomes.

3. **Restricted Food System CM (CHAPEA early trends): M2M by 2027**
4. **Mass Reduced Food System Evaluations: M2M by 2031**
5. **EVA Dietary Requirements: M2M by 2028**

LEGEND: Isolation | Neutral Buoyancy Lab | Atmospheric Chamber | M2M Deliverable

TIMELINE:

1 3 2 5 4

2025 2029 2031 2035

Risk Maps to ESDMD–0305

Immune Risk Approach Plan

HRR Knowledge Gap

Risk Characterization / Formulation

IM-106: Characterize the **effect of the stressors associated with spaceflight** (stress, microgravity, radiation, altered nutrition, circadian misalignment, hypoxia, etc.) on human immunity, determine clinical relevance and biomarkers to enable monitoring of astronauts.



1 **Likelihood and Consequences of Immune Dysfunction/Infectious Disease - ISS: OCHMO by 2026**

2 **Health status Biomarkers Validated – Exploration Missions: M2M by 2033**

CM Development / Evaluation

IM-404: Test, optimize, and validate nutrition, pharmacological, exercise, and stress reduction techniques as **preventive/mitigative countermeasures** for immune dysfunction.

3 **Ground Validation of Immune CMs: M2M by 2027**

4 **Flight Validation of Immune CMs: M2M by 2031**

LEGEND: Isolation | ISS | Neutral Buoyancy Lab | Artemis | M2M Deliverable

TIMELINE: 2025 — 2030 — 2035

1 — 3 — 2

Risk Maps to ESDMD–0305

SANS Risk Approach Plan

HRR Knowledge Gap

Risk Characterization / Formulation

SANS-101: Characterize the **temporal profile and magnitude** of ocular and brain manifestations during spaceflight and recovery to inform in-mission and long-term health consequences.

SANS-102: Characterize the **relationship between fluid shifts-induced ocular changes and fluid shifts** in the CNS, including whether elevated intracranial pressure or brain edema play a role.

SANS-202: Characterize the **inherent factors** (for example, genetic, metabolic, anatomical, sleep) that contribute to the individual variability in the ocular and brain manifestations.

SANS-203: Characterize the effects of **environmental factors** (for example, gravity, atmospheric conditions, radiation) during spaceflight on ocular and brain manifestations.



1 **Personalized SANS Prediction Capability: OCHMO by 2031**
Preliminary version to OCHMO by 2026

2 **LTH Monitoring Surveillance Guidelines: OCHMO by 2036**
Surveillance measures implemented 2029

CM Development / Evaluation

SANS-403: Develop and test **candidate countermeasure(s)** for SANS.

3 **Personalized SANS CMs Prescription (i.e. VTC, B-Complex, GLP-1): M2M by 2031**
B-Complex TTO 2028

SANS-404: Develop and test **candidate monitoring technologies** for SANS.

4 **Ocular monitoring devices: Gateway by 2029, M2M by 2035,**
HRP handover to MCO

LEGEND: ISS · Commercial Freeflyers/PAM · Parabolic Flight · Artemis · Bedrest · M2M Deliverable · Lunar Deliverable

TIMELINE:

2025 — 5 — 1 (2026) — 3 — 2028 — 1 (2031) — 4 — 2 — 2035

Risk Maps to ESDMD–0403

Sensorimotor Risk Approach Plan

HRR Knowledge Gap

Risk Characterization / Formulation

SM-105: Characterize the effects of spaceflight on **manual control and spatial disorientation** during and after G transitions that impact vehicular control.

1 **Manual Control Onboard Training recommendations: Analog 2027 & Flight 2033 to FOD/HLS**

SM-106: Characterize the effects of spaceflight on **postural control and locomotion (gross motor control), and motion sickness** after G transitions that impact egress and early intravehicular / extravehicular activities.

2 **Days post-landing prior to initial EVA: OCHMO by 2033**

CM Development / Evaluation

SM-205: Develop and test **manual control countermeasures**, such as preflight disorientation training, onboard training and adaptive displays that impact vehicular control.



3 **GVS for Preflight disorientation training: HLS by 2027**

4 **Manual Control Adaptive Display and Training Recommendations: HLS by 2027**

1 **Manual Control Onboard Training recommendations: Analog 2027 & Flight 2033 to FOD/HLS**

SM-206: Develop and test **countermeasures for egress, early intravehicular / extravehicular activities, and motion sickness** such as inflight training, post-landing assessments and guidelines, including human factors aids.

5 **Balance Trainer CM Validated: Bedrest 2028, Flight 2031 to M2M**

6 **Pre-EVA SM assessments: Analog 2027 Flight 2031 to SD & EHP**

7 **Head/body motion recovery guidelines: Analog 2027 & Flight 2031 to CCP & OCHMO**

LEGEND: ISS · Centrifuge · Commercial Freeflyers/PAM · Parabolic Flight · Artemis · Bedrest · M2M Deliverable · Lunar Deliverable

TIMELINE: 2025 — 3 4 — 5 — 2030 — 6 Egress — 7 — 1 MC — 2 — 2035

Risk Maps to ESDMD–0402

Venous Thrombosis Risk Approach Plan

HRR Knowledge Gap

Risk Characterization / Formulation

CV-104: Determine **biomarkers** relevant for development of venous thrombosis in spaceflight.

CV-105: Determine the influence of **anatomical variations** for development of venous thrombosis in spaceflight.

CV-106: Determine the influence of **genetic predispositions** for development of venous thrombosis in spaceflight.

CV-107: Determine the influence of **immune factors** for development of venous thrombosis in spaceflight.

CV-108: Determine the contribution of **flow abnormalities** to venous thrombosis risk in 0G and partial-G.

1 **Likelihood and Consequences (LxC) of Venous Thrombosis in 0-G: OCHMO by 2031**

2 **Likelihood and Consequences (LxC) of Venous Thrombosis in partial-G: OCHMO by 2033**

CM Development / Evaluation

CV-202: Identify, develop, and test **monitoring strategies** for venous thrombosis in spaceflight.

CV-203: Identify, develop, and test candidate countermeasures for venous thrombosis in spaceflight.

3 **Thigh Cuffs CM for Venous Thrombosis: OCHMO/M2M by 2032**

4 **Novel CM for Venous Thrombosis (e.g. pharmaceutical/ nutraceutical): OCHMO/M2M by 2035**

LEGEND: CLDP | ISS | Commercial Freeflyers/PAM | Parabolic Flight | Artemis | M2M Deliverable

TIMELINE:

2025 — 2030 — 2035

1 — 2 — 3

Risk Maps to ESDMD–0401